沙库巴曲缬沙坦联合曲美他嗪治疗高血压伴慢性充血性心力衰竭的临床效果分析

Clinical Effect Analysis of Sacubitril Valsartan Combined with Trimetazidine in Treatment of Hypertension with Chronic Congestive Heart Failure

目的:探究沙库巴曲缬沙坦联合曲美他嗪治疗高血压伴慢性充血性心力衰竭的临床效果。方法:选取2021年1月—2022年7月北京市海淀区海淀镇社区卫生服务中心收治的100例高血压伴慢性充血性心力衰竭患者作为研究对象,根据随机数字表法分为对照组和观察组,各50例。对照组采用盐酸曲美他嗪片治疗,观察组在对照组基础上联合沙库巴曲缬沙坦钠片治疗,对比两组心功能相关指标、小腿围、血压水平、生活质量。结果:治疗前,两组氨基末端脑钠肽前体(NT-proBNP)、心输出量(CO)、每搏输出量(SV)、左心射血分数(LVEF)、舒张早期血流速度峰值(E)/舒张晚期血流速度峰值(A)及小腿围比较,差异无统计学意义(P>0.05);治疗后,观察组NT-proBNP、小腿围低于对照组,CO、SV、LVEF、E/A高于对照组,差异有统计学意义(P<0.05)。治疗前,两组收缩压(SBP)、舒张压(DBP)水平比较,差异无统计学意义(P>0.05);治疗后,观察组SBP、DBP水平均低于对照组,差异有统计学意义(P<0.05)。治疗前,两组生理功能、生理职能、躯体疼痛、总体健康、生命活力、社会功能、情感职能、精神健康评分比较,差异无统计学意义(P>0.05);治疗后,观察组生理功能、生理职能、躯体疼痛、总体健康、生命活力、社会功能、情感职能、精神健康评分均高于对照组,差异有统计学意义(P<0.05)。结论:高血压伴慢性充血性心力衰竭患者采取沙库巴曲缬沙坦联合曲美他嗪治疗,能够有效改善临床症状,提高生活质量。

Objective:To explore the clinical effect of sacubitril valsartan combined with trimetazidine in the treatment of hypertension with chronic congestive heart failure.Methods:A total of 100 patients with hypertension and chronic congestive heart failure who were treated in Haidian Town Community Health Service Center of Haidian District of Beijing from January 2021 to July 2022 were selected as the study subjects.They were divided into control group and observation group according to random number table method,with 50 cases in each group.The control group was treated with Trimetazidine Hydrochloride Tablets,and the observation group was treated with Sacubitril Valsartan Sodium Tablets on the basis of control group.The cardiac functionrelated indicators,calf circumference,blood pressure level,and quality of life in two groups were compared.Results:Before treatment,there were no significant differences between the two groups in N-terminal pro-brain natriuretic peptide(NT-proBNP),cardiac output(CO),stroke volume(SV),left ventricular ejection fraction(LVEF),peak early diastolic flow velocity(E)/peak late diastolic flow velocity(A)and calf circumference(P>0.05).After treatment,the NT-proBNP and calf circumference in the observation group were lower than those in the control group,and CO,SV,LVEF,and E/A in the observation group were higher than those in the control group,and the difference was statistically significant(P<0.05).Before treatment,there were no significant differences between the two groups in the levels of systolic blood pressure(SBP)and diastolic blood pressure(DBP)between the two groups(P>0.05).After treatment,the SBP and DBP levels in the observation group were lower than those in the control group,and the difference was statistically significant(P<0.05).Before treatment,there were no significant differences between the two groups in physiological function,physiological functioning,physical pain,overall health,vitality,social function,emotional function,and mental health scores(P>0.05).After treatment,the physiological function,physiological functioning,physical pain,overall health,vitality,social function,emotional function,and mental health scores in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).Conclusion:The treatment of sacubitril valsartan combined with trimetazidine in the patients with hypertension and chronic congestive heart failure can effectively improve clinical symptoms and improve quality of life.